B. Christopher Kim, Ph.D.
Dr. Kim is the Managing Partner of KSLSF. At the time of founding, KSLSF was the first cross-border biotech VC fund and the largest dedicated biotech VC fund in Korea. He is responsible for all aspects of investment, portfolio support and the Fund operations of KSLSF. He co-founded KSLSF as a partner of Oxford Bioscience Partners, an international life sciences venture capital firm located in Boston, MA. Oxford has over $1B under management invested in 149 companies. Prior to KSLSF and Oxford, Dr. Kim served as Associate Director and Head of Operations for the global BioMarker Development group at Novartis Institutes for BioMedical Research. He held additional roles in corporate development and strategy while at Novartis. His other work in the past include IBM Extreme Blue (Emerging Business Opportunity in life sciences) and Alkermes (neuroscience research). Throughout his career, Dr. Kim has served on board of directors or as an advisor to biotech companies, multinational corporation, investment firms and non-profit organizations in both the US and Korea. Dr. Kim received his MBA from Carnegie Mellon University, PhD from University of Texas Health Science Center and the MD Anderson Cancer Center and BA in economics and BS in biology from the UC Irvine. E-mail
Jonathan J. Fleming
Mr. Fleming is a co-founder and General Partner of KSLSF. He is also President and CEO of Q-State Biosciences, an early stage neuroscience company located in Cambridge MA. Since 1996, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners. Mr. Fleming has been in the investment business for nearly 30 years, starting and financing growth companies in the US, Europe, Israel and Asia. Prior to Oxford, he was a founding General Partner of MVP Ventures in Boston. He began his career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Ventures Partners in Israel. He has served on board of directors at numerous biotech companies and non-profit organizations throughout his career. Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers. He holds a MS in Public Administration from Princeton University and a BA in Political Science from UC Berkeley. E-mail
Robert Kamen, Ph.D.
Dr. Kamen has more than 30 years of managerial experience in the biotechnology industry. He was president of the Abbott Bioresearch Center and on Abbott Pharmaceutical’s Executive Management Committee, after serving as BASF Bioresearch Corporation’s president before its acquisition by Abbott. His organization was responsible for the discovery and manufacture of Humira, the anti-TNF monoclonal antibody which is now the world’s top selling drug. Earlier he led research at Genetics Institute, Inc, one of the pioneering biotech companies. He is now an Entrepreneur in Residence with Third Rock Ventures and also serves on several biopharmaceutical company boards and scientific advisory panels. Dr. Kamen graduated from Amherst College with an A.B. (summa cum laude) in biophysics. His doctoral studies at Harvard University in the laboratory of Prof. James D. Watson, resulted in a Ph.D. degree in biochemistry and molecular biology. After a post-doctoral fellowship at the University of Zürich, he moved to the Imperial Cancer Research Fund Laboratories, London, where he was head of its Transcription Laboratory. He is known for his fundamental contributions to the fields of gene expression, RNA stability, molecular virology, molecular oncology and human cytokines.
Brian Seed, Ph.D.
Brian Seed is a Professor of Genetics at Harvard Medical School and a member of the Center for Computational and Integrative Biology at Massachusetts General Hospital. His academic research has centered on the creation and exploitation of genetic selections that can be applied during the transient phase of expression of exogenous genes introduced into mammalian cells, as well as the study of signaling processes in the immune system. His recent interests lie in the identification of new approaches to therapeutic discovery for the creation of biologicals and small molecules that address societally important medical needs. Dr. Seed has been an advisor to large and small biopharmaceutical companies in the US and abroad for many years.